You are here
Ancrod Development Continues to Phase 3 Trial
Paul E. Freiman, President and Chief Executive Officer, stated, "I am highly encouraged by the meeting though more work needs to be done over the next few weeks between the FDA and NTI regarding the design and finalization of the clinical program. We are moving in a careful stepwise fashion to accomplish the goal of entering the clinic this summer."
Viprinex has been studied in more than 2,000 patients in various clinical studies in the U.S. and Europe. The prior development work on Viprinex was conducted by Knoll AG, prior to its acquisition by Abbott in 2001. If successful, we believe that Viprinex may have the potential to double the available treatment window following the onset of stroke symptoms. Currently, the only available therapy for stroke must be administered within the initial three hours, significantly limiting the number of patients that may be treated.
Source: Neurobiological Technologies, Inc.